Lapatinib: current status and future directions in breast cancer

Related Experiment Video

Updated: Jul 18, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Beverly Moy1, Paul E Goss

  • 1Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA.

The Oncologist
|November 18, 2006
PubMed

Insights

Lapatinib, an ErbB-1 and ErbB-2 inhibitor, shows promise in treating breast cancer, including resistant forms and brain metastases. Clinical trials support its role in metastatic and early-stage disease.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Lapatinib is an oral receptor tyrosine kinase inhibitor targeting ErbB-1 and ErbB-2.
  • Pre-clinical studies suggest lapatinib's efficacy as monotherapy and in combination with trastuzumab, even in trastuzumab-resistant models.
  • Early clinical data indicate lapatinib's activity in breast cancer patients.

Purpose of the Study:

  • To review clinical trial results of lapatinib in metastatic breast cancer.
  • To assess lapatinib's potential in patients with brain metastases.
  • To discuss ongoing trials of lapatinib as adjuvant therapy for early-stage breast cancer.

Main Methods:

  • Review of Phase II and III clinical trial data for lapatinib in metastatic breast cancer.
  • Evaluation of evidence regarding lapatinib's efficacy in breast cancer patients with brain metastases.
  • Summary of current clinical trials investigating lapatinib in adjuvant settings for early-stage breast cancer.

Main Results:

  • Lapatinib demonstrates activity in pre-clinical models, including combination therapy with trastuzumab and in resistant cell lines.
  • Clinical trials provide evidence of lapatinib's effectiveness against breast cancer.
  • Potential for lapatinib in treating brain metastases and as adjuvant therapy is under investigation.

Conclusions:

  • Lapatinib is an active agent in breast cancer treatment, with demonstrated efficacy in metastatic disease.
  • Ongoing research explores lapatinib's role in brain metastases and as adjuvant therapy.
  • Advances in breast cancer biology and biomarker identification facilitate the development of targeted therapies like lapatinib.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...